STOCK TITAN
  1. Home
  2. News
  3. VVOS

Vivos Therapeutics Inc - VVOS STOCK NEWS

Welcome to our dedicated news page for Vivos Therapeutics (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vivos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vivos Therapeutics's position in the market.

News
Vivos Therapeutics Closes $4 Million Private Placement
Rhea-AI Summary
Vivos Therapeutics, Inc. has closed a $4 million private placement, with net proceeds of approximately $3.5 million. The company plans to use the funds for general working capital. In the private placement, Vivos issued 980,393 shares of common stock at a purchase price of $4.08 per share. They also issued a Series A Warrant and a Series B Warrant to purchase additional shares. A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
none
-
News
Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Vivos Therapeutics, Inc. has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 980,393 shares of its common stock at a price of $4.08 per share. Additionally, the investor will receive a five-year Series A Warrant and an eighteen-month Series B Warrant to purchase additional shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.19%
Tags
none
-
News
Vivos Therapeutics Announces Reverse Stock Split
Rhea-AI Summary
Vivos Therapeutics, Inc. will undergo a 1-for-25 reverse stock split of its common stock, effective October 27, 2023. The reverse stock split aims to bring Vivos into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The number of outstanding shares will be reduced from 29,928,786 shares to approximately 1,197,151 shares. Shareholders with fractional shares will have them rounded up to the nearest whole share. The exercise prices of outstanding options and warrants will be adjusted accordingly. Vivos' transfer agent, VStock Transfer LLC, will handle the exchange process for stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2229.14%
Tags
none
News
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
Rhea-AI Summary
Vivos Therapeutics signs nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services. Lincare will have a six-month exclusivity to distribute certain designated Vivos devices. This collaboration aims to offer alternative treatment options for sleep apnea patients who discontinue CPAP usage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.76%
Tags
none
-
News
Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine
Rhea-AI Summary
Vivos Therapeutics announces clinical trial using DNA Oral Appliance Therapy to study impact on OSA versus CPAP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
clinical trial
-
News
Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion
Rhea-AI Summary
Vivos Therapeutics, Inc. has entered into an exclusive distribution agreement with NOUM DMCC, a Dubai-based company, to distribute its products in the Middle East-North Africa region. Noum will seek regulatory approvals for Vivos medical devices and has already scheduled a training event for early 2024. Vivos expects revenue from this collaboration in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.89%
Tags
none
News
Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers
Rhea-AI Summary
Vivos Therapeutics announces two key strategic agreements to expand product line and create additional revenue opportunities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
64.86%
Tags
none
-
News
New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference
Rhea-AI Summary
Vivos announces Fifth Annual Breathing Wellness Conference with renowned speakers. Vivos-trained dentists to learn about new services and technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
News
Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
Rhea-AI Summary
Vivos Therapeutics, Inc. reported financial results for Q2 2023, with revenue of $3.4 million, a decrease compared to Q2 2022. Gross profit was $2.1 million, and operating expenses decreased by 31% quarter over quarter and 25% year to date. The company's cost-cutting initiatives led to a reduction in net loss of 21% for Q2 2023. Vivos has treated approximately 40,000 patients with The Vivos Method and trained over 1,800 dentists. They also announced positive results from a clinical study on the treatment of migraine headaches. Vivos anticipates the need for additional financing to achieve cash flow positive operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7%
Tags
earnings
News
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
Rhea-AI Summary
Vivos Therapeutics to release Q2 2023 financial results today after market close. Conference call at 6:00 pm ET to review results and recent milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
earnings
Stock VVOS logo
Vivos Therapeutics Inc

Nasdaq:VVOS

VVOS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

VVOS Stock Data

7.87M
1.93M
7.39%
13.73%
0.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Littleton

About VVOS

vivos therapeutics, inc., a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (sdb) comprising mild-to-moderate obstructive sleep apnea (osa). the company's solutions cover proprietary alternatives for treating mild-to-moderate osa; craniofacial and anatomical anomalies that are associated with mild-to-moderate osa. its treatment for osa involves specially designed and customized oral appliances and treatment protocols. the company, through its vivos integrated healthcare network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate osa. vivos therapeutics, inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals. it caters to general dentists, medical doctors, myofunctional therapists, chiropractors, healthcare providers,